Panel : Debating the Therapeutics Utility of PROTACs & Molecular Glues versus Direct Targeting of RAS to Strategies Best-in-Class Therapeutic Interventions
Time: 12:15 pm
day: Day Two Track A AM
Details:
• What are the advantages of degrading versus direct targeting?
• What are the additional complexities associated with degrader development?
• How to monitor RAS turnover and the kinetics of degradation?
• What is the combination potential of PROTACs?
